Trial Profile
Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Sep 2023
Price :
$35
*
At a glance
- Drugs Cannabidivarin (Primary)
- Indications Pervasive child development disorders
- Focus Therapeutic Use
- 22 Sep 2023 Planned End Date changed from 31 Jul 2023 to 1 Jul 2024.
- 22 Sep 2023 Planned primary completion date changed from 31 Jul 2023 to 1 Jul 2024.
- 21 Sep 2022 Planned End Date changed from 31 Aug 2022 to 31 Jul 2023.